12th A.I.S.F. SPECIAL CONFERENCE 2016

"HCC Italy 2016" Roma, 9.10 Giugno 2016

Giovedì 9 Giugno

SESSIONE 1

Changing epidemiology of HCC in Italy -  G. Svegliati Baroni, Ancona

Surveillance for HCC. Ultrasound at 6 month interval: does one size fits all? - M. Pompili, Roma

SESSIONE 2

Imaging for focal lesions in cirrhosis: which technology and which diagnostic criteria? Clinical questions and radiological answers

- M. Renzulli, Bologna
- A. Sangiovanni, Milano

When and how biopsy for HCC in 2016? - F. Farinati, Padova

Real life clinical scenarios 2

- A. Granito, Bologna
- F. Morisco, Napoli
- L. Romanini, Brescia

SESSIONE 3

Staging and prognostic systems: beyond BCLC? - A. Vitale, Padova

SESSIONE 4

Composition and benefits of multidisciplinary board meetings - A. Gasbarrini, Roma

Prevention of first HCC in cirrhosis: are HCV eradication or HBV suppression sufficient in the age of direct-acting antivirals? - A. Craxì, Palermo

Prevention of recurrent HCC - M. Colombo, Milano

SESSIONE 5

Management of antiplatelet and anticoagulant drugs in patients with HCC to be submitted to interventional procedures - M. Senzolo, Padova

Radioembolization: technical aspects - R. Golfieri, Bologna

Clinical scenario - F. Trevisani, Bologna (in attesa di autorizzazione)

Preliminary experience with Hadrontherapy in HCC - R. Orecchia, Milano

Venerdì 10 Giugno

SESSIONE 6

Preamble: which are the reasons behind low adherence to BCLC treatment algorithm in real life? - L. Bolondi, Bologna

Percutaneous ablation: indications, techniques and results - G.G. Di Costanzo, Napoli

Controversies in surgical approach to HCC (with televoter) 

a) Clinical scenarios: liver dysfunction, liver stiffness and/or portal hypertension - M. Cescon, Bologna

b) Clinical scenarios: multinodularity/multimodality - G. Torzilli, Milano

SESSIONE 7

When to refer HCC patients to the transplant center and how to implement the benefit principle? - U. Cillo, Padova

SESSIONE 8

Transarterial chemoembolization: indications to first treatment - M. De Giorgio, Bergamo

Transarterial chemoembolization: modalities and agents in 2016 - I. Bargellini Pisa

Transarterial chemoembolization: when to repeat, when to combine and when to stop? - M. Iavarone, Milano

SESSIONE 9

Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval - A. Santoro, Milano

Results of systemic treatment trials (1st and 2nd line) after SHARP, reasons for failures and natural history of untreated patients - G. Cabibbo, Palermo

Future drugs for patients not tolerating or progressing under Sorafenib - F. Piscaglia, Bologna

Advanced HCC. Clinical scenarios with televoter - G. Cabibbo, Palermo – R. Sacco, Pisa

SESSIONE 10

Basics of immunity and immunotherapy for HCC - L. Buonaguro, Napoli

External radiation therapy for HCC: palliative care and stereotactic treatments - M. Scorsetti, Milano (in attesa di autorizzazione)

Palliative care: pain management and end of life assistance for HCC on cirrhosis - A. Turriziani, Roma